MedinCell S.A.
MEDCL.PA · PAR
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | €26 | €9 | €10 | €4 |
| % Growth | 178.8% | -7.9% | 143.1% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €26 | €9 | €10 | €4 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | €24 | €21 | €28 | €24 |
| G&A Expenses | €0 | €9 | €7 | €6 |
| SG&A Expenses | €1 | €12 | €10 | €8 |
| Sales & Mktg Exp. | €1 | €3 | €3 | €2 |
| Other Operating Expenses | €12 | -€2 | €0 | €0 |
| Operating Expenses | €36 | €30 | €34 | €28 |
| Operating Income | -€11 | -€21 | -€24 | -€24 |
| % Margin | -42.4% | -229% | -241.6% | -582.2% |
| Other Income/Exp. Net | -€7 | -€4 | -€8 | -€1 |
| Pre-Tax Income | -€18 | -€25 | -€32 | -€25 |
| Tax Expense | €0 | €0 | €0 | €0 |
| Net Income | -€18 | -€25 | -€32 | -€25 |
| % Margin | -72.2% | -273.3% | -321.9% | -606.5% |
| EPS | -0.63 | -0.88 | -1.27 | -1 |
| % Growth | 28.4% | 30.7% | -27% | – |
| EPS Diluted | -0.63 | -0.88 | -1.27 | -1 |
| Weighted Avg Shares Out | 29 | 28 | 25 | 25 |
| Weighted Avg Shares Out Dil | 29 | 28 | 25 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | -€0 | €0 | €0 |
| Interest Expense | €5 | €5 | €4 | €2 |
| Depreciation & Amortization | €2 | €2 | €2 | €2 |
| EBITDA | -€11 | -€19 | -€26 | -€21 |
| % Margin | -43.9% | -203.2% | -265.6% | -524.4% |